BSX
BOSTON SCIENTIFIC CORP
Healthcare • NYSE • CIK 0000885725
Loading...
Market Cap
$63.26B
P/E (TTM)
17.6x
Rev Growth (TTM)
+13.5%
Net Margin (TTM)
17.5%
FCF Yield (TTM)
5.7%
FCF Margin (TTM)
17.3%
Figures as of June 30, 2026
Filings
Primary-source SEC disclosures, read end-to-end — every figure traceable to its filing.
8-KSep 20262026-09-23source
8-KSep 20262026-09-08source
8-KAug 20262026-08-26source
10-Q2026 Q22026-08-03source
8-KEarnings2026-07-29source
What your agent reads
Investor Relations
Company-published material — management’s own words, not SEC-audited. Each source below is labeled so your agent knows what to verify.
Company-published, not SEC-audited
Earnings
Q2
2 months ago
8-K releaseRevenue
$5.44B
+7.5%
Net Income
$907.00M
+13.8%
EPS
N/A
—
Most recent quarterly earnings snapshot
Cash Flow Health
Free Cash Flow8/8 positive
TTM$3.6B
Q2 '26
$1.3B+648%
Q1 '26
$171.0M-83%
FCF Margin
TTM17.3%
Q2 '2623.5%+615%
Sector: 0.7%Top 25%
OCF Margin
21.6%
OCF/NI1.23x
CapEx Coverage
5.0x
FCF Yield5.7%
FCF Growth (3Y)+34%
Cash Conversion Cycle
110 days
DSO: –+DIO: 174−DPO: 63
Cash flow trends & capital efficiency
Capital Allocation
Total Shareholder Yield
TTM0.0%
Dividend & Payout Metrics
Dividend Yield (TTM)—
Free Cash Flow (TTM)$3.6B
Capital Return / FCF0.0%
Shares Outstanding (YoY)-2.2%↓ Buyback
Buyback data not disclosed in this company's filings.
Shows how management rewards shareholders
Valuation Metrics
Price-to-EarningsTTM
17.6x
Volatile
8Q: 51.3x-4636%
Valuation Lenses
Earnings
17.6x
vs – sector
Cash Flow
20.8x
EV/FCF vs –
Growth-Adj
0.4xPEG
Undervalued for growth
Quality-Adj
1.6P/E per %ROIC
ROIC: 11.0%
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap$63.26B
EV$75.34B
Multi-angle valuation analysis with sector context
Margins & Efficiency
ROIC 75th pctile
Profitability Cascade
Gross
69.9%
Operating
19.8%
Top 25% in sector
Net
17.5%
Margins Unknown
Return on Invested CapitalTTM
11.0%
Stable
+0.0% YoY8Q: 9.1%+5.0%
P25MedianP75
75th pctl (med: -7.4%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
18.8%
8Q: 15.7%
Asset Turnover
0.48x
8Q: 0.48x
Leverage (1+D/E)
1.51x
D/E: 0.51x
DuPont: 13.7% ≈ 11.0% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
5.35x
8Q:5.58x
-47.9%
Invested Cap Turn
0.64x
8Q:0.64x
Flat
CapEx Intensity
2.8%
8Q:2.5%
CapEx/Depreciation
0.64x
FCF vs Net Margin Gap-0.2 pts
Margin trends, ROIC, and capital efficiency
Balance Sheet & Solvency
ND/EBITDA 1.8x
Net Debt / EBITDA
1.8xNet Debt: $12.09B
Interest Coverage
11.4x
+Strong interest coverage: 11.4x
Leverage Metrics
Debt-to-Equity
0.51x
Balance sheet risk & solvency analysis
Related Research
2 related posts